ABIVAX Société Anonyme/€ABVX

Abivax shares fall as broad risk aversion, increased short positioning and caution ahead of the 21 September H1 2026 results weigh on the biotech.
6 hours agoLightyear AI
1D1W1MYTD1Y5YMAX

About ABIVAX Société Anonyme

Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.
Ticker
€ABVX
Sector
Health
Primary listing
PAR
Employees
80
Headquarters
Paris, France
Website
www.abivax.com

ABVX Metrics

BasicAdvanced
€8.7B
-
-€4.52
-0.25
-

Bulls say / Bears say

Obefazimod produced unusually strong Phase 3 maintenance results in ulcerative colitis: clinical remission was 50.8% with 25 mg and 51.3% with 50 mg, versus 10.4% for placebo. Both doses also met all key secondary endpoints, supporting a potentially differentiated product profile. (Abivax, BioPharma Dive)
The company completed a positive pre-NDA interaction with the FDA, which supported its planned submission strategy and kept the ulcerative colitis filing on track for the end of 2026. This reduces uncertainty around the immediate regulatory route, although it is not yet an approval. (Abivax)
Longer-term data provide evidence that the treatment effect can persist: 68% of patients who reduced their dose after two to four years on 50 mg remained in clinical remission at week 144. The same update reported no new safety signals in patients treated for up to seven years. (BioSpace)
Several malignancy events occurred in the 50 mg arm of the Phase 3 maintenance trial, including prostate cancer, breast cancer and colonic dysplasia, alongside skin cancers. Investigators judged the events unrelated or unlikely to be related, but the cluster has weakened what had been a key safety advantage and could affect the eventual label. (STAT News, Endpoints News)
Abivax remains dependent on one lead clinical asset while regulatory and commercial execution are still ahead. The Crohn’s disease programme is only in Phase 2b, with results expected in mid-2027, so a setback in approval or launch would leave little near-term diversification. (CNBC, Abivax)
The company raised $800 million through a 6.4-million-ADS offering to fund US commercialisation and further trials, increasing its financial flexibility but also diluting existing shareholders before product revenue is established. It had already issued additional shares in May to repurchase royalty certificates. (Abivax, Abivax)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

Funds containing ABVX

AllEURGBPUSD
Funds
Fund name
Fund size
€ABVX weighting
iShares EURO STOXX Mid€DJMC
€572M0.95%
iShares EURO STOXX Mid Cap£DJMC
£491M0.95%
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.50%
iShares Nasdaq US Biotechnology£BTEK
£865M0.50%
iShares STOXX Europe Mid 200€EXSD
€610M0.44%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.